All Stories

  1. Tape stripped stratum corneum samples are suitable for diagnosis and comprehensive proteomic investigation in mycosis fungoides
  2. Genomic and proteomic findings in early melanoma and opportunities for early diagnosis
  3. Informing a position statement on the use of artificial intelligence in dermatology in Australia
  4. Supine dermoscopy for improved visualisation of lower limb lesions
  5. Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry ( MelCOR ): A modified Delphi study
  6. Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma
  7. Management of genital hidradenitis suppurativa and lymphoedema with the restoration of erectile function
  8. Warfarin‐induced skin necrosis after the use of an anticoagulation reversal agent
  9. ¿Cuánta carga asistencial suponen las infecciones de transmisión predominantemente sexual y otras dermatosis anogenitales en las consultas de Dermatología en España? Resultados del muestreo aleatorio nacional DIADERM
  10. Merkel cell carcinoma in situ: A systematic review of prognosis and management
  11. Association Between Melanoma Detected During Routine Skin Checks and Mortality
  12. Australian baseline series allergens in assessment of allergic contact dermatitis in New South Wales
  13. Toxic epidermal necrolysis‐like lupus erythematosus: a condition to exclude in all patients with possible Stevens‐Johnson syndrome/toxic epidermal necrolysis
  14. Adherence to suggestions after dermatology consultation in a tertiary hospital – a retrospective analysis
  15. Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition
  16. Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas
  17. Specialised skin cancer spectral library for use in data‐independent mass spectrometry
  18. Uncovering the unmet needs among psoriasis patients in the Asia‐Pacific region
  19. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7
  20. Dermatology inpatient consultations in a tertiary hospital – a retrospective analysis
  21. ¿Cuánta carga asistencial supone la enfermedad tumoral cutánea en la actividad ambulatoria en la Dermatología española? Resultados del muestreo aleatorio nacional DIADERM
  22. Mass spectrometry‐based proteomic analysis of the effect of storage temperature on non‐invasively collected samples of human stratum corneum
  23. Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin Surveillance
  24. Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
  25. Prevalence of skin examination behaviours among Australians over time
  26. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
  27. Successful treatment of highly refractory necrobiotic xanthogranuloma with peginterferon alfa‐2a
  28. Reflectance confocal microscopy role in mycosis fungoides follow‐up
  29. Investigating proteome changes between primary and metastatic cutaneous squamous cell carcinoma using SWATH mass spectrometry
  30. Widespread nodules and papules in a patient with chronic myelomonocytic leukemia
  31. Allergic Contact Dermatitis of the Anogenital Region in Men and Women
  32. Proteomics: An emerging approach for the diagnosis and classification of cutaneous squamous cell carcinoma and its precursors
  33. Reflectance confocal microscopy as a new diagnostic tool in transformed mycosis fungoides
  34. Mohs Micrographic Surgery in Patients Younger Than 40 Years
  35. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia
  36. Mohs Micrographic Surgery at the Skin and Cancer Foundation Australia, 20 Years Later (1997–2017)
  37. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events
  38. Data Independent Acquisition Proteomic Analysis Can Discriminate between Actinic Keratosis, Bowen’s Disease, and Cutaneous Squamous Cell Carcinoma
  39. Systematic review and proposal of an in vivo reflectance confocal microscopy assessment tool for cutaneous lymphoma
  40. Incidence of cardiovascular events among tildrakizumab‐treated patients with moderate‐to‐severe plaque psoriasis: pooled data from three large randomised clinical trials
  41. Increased collaboration between Mohs and plastic surgeons in the surgical management of skin cancer in Australia
  42. Do Dermatologic Diagnosis Change in Hot vs Cold Periods of The Year? A Sub-Analysis of the DIADERM National Sample (Spain 2016)
  43. Análisis de la proporción de derivaciones potencialmente evitables desde Atención Primaria a Dermatología por lesiones quísticas o tumorales benignas en España. Datos del estudio DIADERM
  44. Keratinocyte carcinoma as a chronic disease in Australia and Spain: The importance of avoidance of perceived visible scars
  45. Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma
  46. ¿Existe variación en los diagnósticos dermatológicos entre la temporada de frío vs. calor? Un subanálisis del estudio DIADERM (España 2016)
  47. Neurocognitive Function and Quality of Life Outcomes in the ONTRAC Study for Skin Cancer Chemoprevention by Nicotinamide
  48. Derivación de pacientes en consulta de dermatología y de teledermatología en España. Estudio DIADERM
  49. Management of cutaneous T-cell lymphomas: Established and emergent therapies
  50. Vitiligo‐like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers
  51. Use of immortal time within survival analysis
  52. Patch Testing for Cheilitis
  53. Public body consciousness is associated with positive tanning attitudes and behaviours regardless of gender or age
  54. Anti-programmed cell death-1 therapy-associated bullous disorders
  55. Problemas de la CIE-10 para la codificación de diagnósticos dermatológicos. Estudio DIADERM
  56. Risk Perception Plays Minimal Role in Sun Exposure Behaviours
  57. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study
  58. Tape Stripped Stratum Corneum Samples Prove to be Suitable for Comprehensive Proteomic Investigation of Actinic Keratosis
  59. Tanning, selfies and social media
  60. Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey
  61. Differential proteomic analysis of actinic keratosis, Bowen’s disease and cutaneous squamous cell carcinoma by label-free LC–MS/MS
  62. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma
  63. Outpatient Dermatological Diagnoses in Spain: Results From the National DIADERM Random Sampling Project
  64. Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas
  65. The efficacy and safety of methotrexate versus interferon in cutaneous T-cell lymphomas
  66. Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II
  67. Cutaneous non-tuberculous mycobacteria in Western Sydney, Australia. Population study 1996-2013
  68. Pigmentary evolution with pembrolizumab use
  69. Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils
  70. Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis
  71. Management of the cutaneous adverse effects of antimelanoma therapy
  72. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab)
  73. Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone
  74. PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation-Report of 4 cases
  75. Atypical fibroxanthoma management: Recurrence, metastasis and disease-specific death
  76. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study
  77. Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)
  78. Self-directed tablet education session improves safety knowledge among patients undergoing phototherapy
  79. Scar outcomes in dermatological surgery
  80. Experience of skin cancer and contact with health professionals is associated with increased skin cancer knowledge, but not sun safety knowledge or behaviour
  81. Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib
  82. Cutaneous Nodules in the Genital Area in a Patient With Chronic Graft-vs-Host Disease
  83. Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis
  84. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management
  85. Cutaneous Side Effects of Single Versus Combined BRAF Inhibitors: A Comment to Erfan et al.
  86. Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death–1 (anti–PD-1) Therapy With or Without Ipilimumab
  87. Why do young adults tan?
  88. Nicotinamide: New Indications in Dermatology
  89. FR - Nuevas indicaciones de nicotinamida en dermatología
  90. In Silico Analysis Validates Proteomic Findings of Formalin-fixed Paraffin Embedded Cutaneous Squamous Cell Carcinoma Tissue
  91. Systemic and erythrodermic reactions following repeated exposure to bites from the Common bed bug Cimex lectularius (Hemiptera: Cimicidae)
  92. Objective severity does not capture the impact of rosacea, acne scarring and photoaging in patients seeking laser therapy
  93. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma
  94. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies
  95. Classification of high risk basal cell carcinoma subtypes: experience of the ONTRAC study with proposed definitions and guidelines for pathological reporting
  96. PD-1 inhibitors induced bullous lichen planus-like reactions
  97. Transient acantholytic dyskeratosis (Grover's disease) after bone marrow transplantation
  98. Mechanisms of BRAFi-induced hyperproliferative cutaneous conditions
  99. Direct Cost-Analysis of Mohs Micrographic Surgery and Traditional Excision for Basal Cell Carcinoma at Initial Margin Clearance
  100. Sun Exposure Habits and Sun Protection Practices of Skaters
  101. Toxic Epidermal Necrolysis–like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma
  102. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort
  103. Factors affecting choice of repair in Mohs micrographic surgery for non-melanoma skin cancer of the head
  104. The microbiome and atopic eczema: More than skin deep
  105. Treatment-specific utility weightings are needed for cost-utility analysis in metastatic melanoma
  106. Time-Dependent Measurement of Adverse Events
  107. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention
  108. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma
  109. Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice
  110. Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone
  111. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab
  112. Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia
  113. Dermatology Over the Rainbow
  114. Factors influencing the development of cutaneous squamous cell carcinoma in patients on BRAF inhibitor therapy
  115. Treatment of face and scalp solar (actinic) keratosis with daylight-mediated photodynamic therapy is possible throughout the year in Australia: Evidence from a clinical and meteorological study
  116. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma
  117. Gemcitabine and vinorelbine treatment in cutaneous T-cell lymphoma in four patients
  118. Cutaneous non-tuberculous mycobacterial infection in patients with chronic graft-versus-host disease: A case series
  119. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks
  120. Dabrafenib-associated necrobiotic granulomatous reaction
  121. Phototherapy for the treatment of cutaneous graft versus host disease
  122. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy
  123. Quality of life in non-melanoma skin cancer
  124. Diffuse melanosis cutis in the setting of BRAFV600Emutant melanoma and treatment with targeted therapies
  125. Panniculitis in Patients Treated With BRAF Inhibitors
  126. Topical corticosteroids
  127. BRAF Inhibitor Induced Verrucal Keratosis
  128. Behaviour, attitudes and awareness concerning sun exposure in adolescents on the Costa del sol
  129. Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib
  130. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors
  131. An analysis of the dermatological uses of mycophenolate mofetil in a tertiary hospital
  132. Localized cutaneous immunoglobulin G4
  133. Rational use of topical corticosteroids
  134. Non-evolving linear facial plaque
  135. Cutaneous toxicities of RAF inhibitors
  136. Lichen Planus-Like Drug Eruptions Due to β-Blockers
  137. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
  138. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors
  139. Erythema ab igne as a differential diagnosis of chronic graft versus host disease (GVHD)
  140. Systemic Retinoid Therapy for Chemoprevention of Nonmelanoma Skin Cancer in a Patient Treated With Vemurafenib
  141. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis
  142. Bed Bugs: Clinical Relevance and Control Options
  143. Lack of efficacy of rituximab in refractory sclerodermatous chronic GVHD
  144. Sarcoidosis, Hypercalcemia and Calcium-sensing Receptor Mutation: A Case Report
  145. Mohs micrographic surgery at the Skin and Cancer Foundation Australia, 10 years later (1997 vs 2007)
  146. Potent topical steroids are one of the treatments for cutaneous T-cell lymphoma
  147. Cutaneous epithelioid angiosarcoma occurring at a peristomal site
  148. Many faces of graft-versus-host disease
  149. Squamous cell carcinoma arising in a recent plaque of discoid lupus erythematous, in a sun-protected area
  150. Stage IV cutaneous acute graft-versus-host disease. Clinical and histological study of 15 cases
  151. Array-CGH Reveals Recurrent Genomic Changes in Merkel Cell Carcinoma Including Amplification of L-Myc
  152. Pachyonychia congenita and hidradenitis suppurativa: no response to infliximab therapy
  153. Las cabinas de bronceado, el cáncer de piel, los estándares internacionales y la función social del dermatólogo
  154. Cutaneous lichenoid graft-versus-host disease mimicking lupus erythematosus
  155. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features
  156. Self-Reported Adherence to Treatment and Quality of Life in Mild to Moderate Acne
  157. Alopecia syphilitica with detection of Treponema pallidum in the hair follicle
  158. Eosinophilic folliculitis following allogeneic peripheral blood stem cell transplantation: case report and review
  159. A Polypodium leucotomos extract inhibits solar-simulated radiation-induced TNF-? and iNOS expression, transcriptional activation and apoptosis
  160. Use of Biological Agents in Patients With Moderate to Severe Psoriasis
  161. Hidrosadenitis supurativa. Respuesta al tratamiento con infliximab
  162. Stellate hypopigmented macules and papules on photoexposed areas
  163. Quality of life in mild to moderate acne: relationship to clinical severity and factors influencing change with treatment
  164. Luz ultravioleta e inmunidad
  165. The clinical and histologic spectrum of chronic graft-versus-host disease
  166. Atypical Early Follicular Graft-vs-Host Disease
  167. Sentinel Lymph Node Biopsy for Evaluation and Treatment of Patients With Merkel Cell Carcinoma
  168. Acute severe form of lichenoid graft-versus-host disease after donor lymphocyte infusions
  169. Implication of MT1-MMP in the maturation steps of benign melanocytic nevi
  170. O'Brien actinic granuloma presenting as alopecia
  171. Role of Tetraspanins CD9 and CD151 in Primary Melanocyte Motility
  172. Solar-Simulated Ultraviolet Radiation Induces Abnormal Maturation and Defective Chemotaxis of Dendritic Cells
  173. Percepción subjetiva del dolor en cirugía local dermatológica
  174. A severe case of pachyonychia congenita type I due to a novel proline mutation in keratin 6a
  175. Inhibición de la motilidad de células de melanoma con ARN de interferencia de CD9
  176. Maculopapular eruption with enlarged macrophages in eight patients receiving G-CSF or GM-CSF
  177. Calidad de vida en dermatología
  178. Dermatologic Treatment of Cutaneous Graft Versus Host Disease
  179. Erupción por factores estimuladores de colonias granulocíticas en un paciente con leucemia mieloide crónica
  180. Diagnostic and neural analysis of skin cancer (DANAOS). A multicentre study for collection and computer-aided analysis of data from pigmented skin lesions using digital dermoscopy
  181. Pustular acral erythema in a patient with acute graft-versus-host disease
  182. Perianal Lentiginosis: A Case of Localized Lentiginosis
  183. Poliangeítis microscópica
  184. Sclerodermatous Graft-vs-Host Disease
  185. Calidad de vida (II). Calidad de vida en Dermatología
  186. Infección cutánea por Mycobacterium chelonae. Revisión de seis casos
  187. Calidad de vida (I). Generalidades
  188. Anticuerpos monoclonales en el tratamiento de la psoriasis
  189. La versión española de Skindex-29. Un instrumento de medida de la calidad de vida en pacientes con enfermedades cutáneas
  190. La teledermatología hoy
  191. The Spanish version of Skindex-29
  192. Association of Helicobacter pylori Infection With Psoriasis and Lichen Planus: Prevalence and Effect of Eradication Therapy
  193. Tetraspanins are Localized at Motility-Related Structures and Involved in Normal Human Keratinocyte Wound Healing Migration
  194. A Follicular Lichenoid Eruption as Manifestation of Chronic Graft-vs-Host Disease
  195. Reply
  196. Differential Expression of Activation Epitopes of β1 Integrins in Psoriasis and Normal Skin
  197. D - Penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1 in a patient with mixed connective tissue disease
  198. Perforating granuloma annulare
  199. Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur.
  200. Pseudoxanthoma elasticum-like papillary dermal elastolysis. A report of two cases and review of the literature.
  201. Reply
  202. Condyloma-like lesions as the presenting sign of multiple Myeloma associated amyloidosis
  203. Leishmaniasis presenting as a dermatomyositis-like eruption in AIDS
  204. Post-Kala-Azar Dermal Leishmaniasis in an HTV-Patient
  205. Microscopic polyangiitis. A systemic vasculitis with a positive P-ANCA
  206. Leukocytoclastic Vasculitis in Subacute Cutaneous Lupus Erythematosus: Clinicopathologic Study of Three Cases and Review of the Literature
  207. Malignant melanoma appearing in a seborrhoeic keratosis
  208. Recall phenomenon with the unusual presence of eccrine squamous syringometaplasia
  209. Cutaneous Heterotopic Meningeal Nodules
  210. Cutaneous lesions as the first sign of disseminated mucormycosis.
  211. Lichen amyloidosus and Human Immunodeficiency Virus Infection
  212. Reticular Erythematous Mucinosis Associated with Human Immunodeficiency Virus Infection
  213. Cutaneous T-cell lymphoma and myelodysplastic syndrome
  214. Treatment of mycosis fungoides with etretinate and low-dose interferon α2a
  215. Cutaneous meningioma underlying congenital localized hypertrichosis
  216. Keratosis punctata of the Palmar Creases: Case Report and Prevalence Study in Caucasians
  217. Mechanism of mannose toxicity